Short answer
10x Genomics, Inc. (TXG) filed its Q1 2026 10-Q quarterly report on May 8, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $151M (down 2.6% year over year) with net income of −$13M.
Q1 2026 key financials · XBRL
- Revenue
- $151M
- −2.6% YoY
- Net income
- −$13M
- +60.8% YoY
- Operating margin
- -11.3%
- Gross margin
- 70.4%
- EPS (diluted)
- −$0.10
- +64.3% YoY
Source: XBRL data from the 10x Genomics, Inc. (TXG) Q1 2026 10-Q on SEC EDGAR. USD.
10x Genomics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $150.8M, down 3% YoY from $154.9M
- Gross margin 70% vs 68% YoY; gross profit $106.2M vs $105.4M
- Best line Spatial consumables $40.9M, up 31%; worst Spatial instruments $6.0M, down 32%
- Cash and securities $539.8M, up $16.4M; operating cash flow $26.1M vs $34.4M
- Outlook: moderate revenue increase and modest operating-expense decrease in 2026, excluding non-recurring 2025 settlements
Risk Factors
- No material changes to previously disclosed 10-K risk factors
- Scale Biosciences milestone payment: 396,584 unregistered shares valued at $8.7 million
- Securities issuance relied on Securities Act Section 4(a)(2) private-placement exemption
- Director Rule 10b5-1 plan covers up to 28,616 shares through June 30, 2027
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other 10x Genomics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.